Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

Novo Nordisk Canada announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental ...

A recent study reveals that semaglutide, a diabetes medication known for its weight-loss effects, shows promise in treating ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

Semaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition.

An international study led by the director of Virginia Commonwealth University’s liver institute suggests that the substance ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic dysfunction-associated steatohepatitis and moderate or advanced liver ...